AETHLON MEDIC.NEW DL-001
Research AETHLON MEDIC.NEW DL-001 (EJU) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerEJU
- ExchangeSTU
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.88M
- Free cash flow-USD 1.75M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 11.52M | -USD 6.92M | n/a | n/a | USD 6.96M | USD 417.52K | USD 6.71M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About AETHLON MEDIC.NEW DL-001
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does AETHLON MEDIC.NEW DL-001 do?
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.